Expression of an exogenous human Oct-4 promoter identifies tumor-initiating cells in osteosarcoma

Cancer Research

Volumn 69, Issue 14, 2009, Pages 5648-5655

  Levings, Padraic P ^a   McGarry, Sean V ^c   Currie, Thomas P ^a   Nickerson, David M ^d   McClellan, Steven ^b   Ghivizzani, Steven C ^a   Steindler, Dennis A ^a   Gibbs, C Parker ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d UNIVERSITY OF CENTRAL FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOGLIN; GREEN FLUORESCENT PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; OCTAMER TRANSCRIPTION FACTOR 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CARCINOGENESIS; CHILD; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OSTEOSARCOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR BIOPSY; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, CD; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR ADHESION MOLECULE-1; MICE; MICE, INBRED NOD; MICE, SCID; MICROSCOPY, FLUORESCENCE; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; OSTEOSARCOMA; PROMOTER REGIONS, GENETIC; RECEPTORS, CELL SURFACE; SARCOMA, EXPERIMENTAL; TIME FACTORS; TRANSFECTION;

EID: 67651005780     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3580     Document Type: Article

References (42)

1. Gibbs CP, Kukekov VG, Reith JD, et al. Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 2005;7:967-76.
2. Jaffe N, Carrasco H, Raymond K, Ayala A, Eftekhari F. Can cure in patients with osteosarcoma be achieved exclusivelyw ith chemotherapy and abrogation of surgery? Cancer 2002;95:2202-10.
3. Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005;23:2004-11.
4. Bruland OS, Pihl A. On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer 1997;33:1725-31.
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
6. Dick JE. Stem cell concepts renew cancer research. Blood 2008;112:4793-807.
7. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-68.
8. Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells - perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 2006;66:9339-44.
9. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biologyto cancer. Nat Rev Cancer 2003;3:895-902.
10. Klein MJ, Siegal GP. Osteosarcoma: anatomic and histologic variants. Am J Clin Pathol 2006;125:555-81.
11. Unni KK. Osteosarcoma of bone. J Orthop Sci 1998;3:287-94.
12. Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD, Steindler DA. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro . Glia 2002;39:193-206.
13. Gerrard L, Zhao D, Clark AJ, Cui W. Stably transfected human embryonic stem cell clones express OCT4-specific green fluorescent protein and maintain self-renewal and pluripotency. Stem Cells 2005;23:124-33.
14. Cho RW, Clarke MF. Recent advances in cancer stem cells. Curr Opin Genet Dev 2008;18:48-53.
15. Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Annu Rev Cell Dev Biol 2007;23:675-99.
16. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med 2007;58:267-84.
17. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-8.
18. Dalerba P, Dylla SJ, Park IK, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 2007;104:10158-63.
19. Heidemann J, Maaser C, Lugering A, et al. Expression of vascular cell adhesion molecule-1 (CD106) in normal and neoplastic human esophageal squamous epithelium. Int J Oncol 2006;28:77-85.
20. Osta WA, Chen Y, Mikhitarian K, et al. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 2004;64:5818-24.
21. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-10.
22. Hamburger A, Salmon SE. Primary bioassay of human myeloma stem cells. J Clin Invest 1977;60:846-54.
23. Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science 1977;197:461-3.
24. Hamburger AW, Salmon SE, Kim MB, et al. Direct cloning of human ovarian carcinoma cells in agar. Cancer Res 1978;38:3438-44.
25. Page RH, Tilchen EJ, Davis HL. Effects of tumor cell viability and inoculum density on growth parameters in the human tumor, soft-agar clonogenic assay. Cancer Res 1988;48:3944-8.
26. Gibbs CP, Jr., Weber K, Scarborough MT. Malignant bone tumors. Instr Course Lect 2002;51:413-28.
27. Liedtke S, Stephan M, Kogler G. Oct4 expression revisited: potential pitfalls for data misinterpretation in stem cell research. Biol Chem 2008;389:845-50.
28. Zuk PA. The intracellular distribution of the ES cell totipotent markers OCT4 and Sox2 in adult stem cells differs dramaticallyaccord ing to commercial antibody used. J Cell Biochem 2009;106:867-77.
29. Veraitch FS, Scott R, Wong JW, Lye GJ, Mason C. The impact of manual processing on the expansion and directed differentiation of embryonic stem cells. Biotechnol Bioeng 2008;99:1216-29.
30. Yeom YI, Fuhrmann G, Ovitt CE, et al. Germline regulatory element of Oct-4 specific for the totipotent cycle of embryonal cells. Development 1996;122:881-94.
31. Ohmura M, Yoshida S, Ide Y, Nagamatsu G, Suda T, Ohbo K. Spatial analysis of germ stem cell development in Oct-4/EGFP transgenic mice. Arch Histol Cytol 2004;67:285-96.
32. Boiani M, Eckardt S, Scholer HR, McLaughlin KJ. Oct4 distribution and level in mouse clones: consequences for pluripotency. Genes Dev 2002;16:1209-19.
33. Do JT, Scholer HR. Nuclei of embryonic stem cells reprogram somatic cells. Stem Cells 2004;22:941-9.
34. Han DW, Do JT, Gentile L, Stehling M, Lee HT, Scholer HR. Pluripotential reprogramming of the somatic genome in hybrid cells occurs with the first cell cycle. Stem Cells 2008;26:445-54.
35. Huangfu D, Osafune K, Maehr R, et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol 2008;26:1269-75.
36. Tada M, Tada T, Lefebvre L, Barton SC, Surani MA. Embryonic germ cells induce epigenetic reprogramming of somatic nucleus in hybrid cells. EMBO J 1997;16:6510-20.
37. Tada M, Takahama Y, Abe K, Nakatsuji N, Tada T. Nuclear reprogramming of somatic cells by in vitro hybridization with ES cells. Curr Biol 2001;11:1553-8.
38. Miremadi A, Oestergaard MZ, Pharoah PD, Caldas C. Cancer genetics of epigenetic genes. Hum Mol Genet 2007;16 Spec No 1:R28-49.
39. Shukla V, Vaissiere T, Herceg Z. Histone acetylation and chromatin signature in stem cell identity and cancer. Mutat Res 2008;637:1-15.
40. Dalerba P, Clarke MF. Cancer stem cells and tumor metastasis: first steps into uncharted territory. Cell Stem Cell 2007;1:241-2.
41. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194:23-8.
42. Peabody TD, Gibbs CP, Jr., Simon MA. Evaluation and staging of musculoskeletal neoplasms. J Bone Joint Surg Am 1998;80:1204-18.